XML 36 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events
18.
Subsequent Events

Acquisition of Bioprocessing Analytics Portfolio from 908 Devices Inc.

On March 4, 2025, the Company entered into a Securities and Asset Purchase Agreement with 908 Devices Inc. ("908 Devices") to acquire their desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices is headquartered in Boston, Massachusetts. The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies.

The Company will account for the 908 Devices Acquisition as a purchase of a business under the acquisition method of accounting and has engaged a third-party valuation firm to assist with the valuation of the business acquired. The required disclosures under ASC 805, "Business Combinations" will be included in the Quarterly Report on Form 10-Q for the period ended March 31, 2025.